SpacDeskBiotech & Pharma SPACs
5 active SPACs targeting Biotech & Pharma with $1.0B in trust.
The Biotech & Pharma sector currently hosts five active SPAC vehicles with approximately $1.0 billion in aggregate capital deployed. Two blank-check companies remain in active search mode seeking life sciences targets, while three have announced definitive business combinations. The median days-to-expiration across these vehicles stands at 385, reflecting a range of timeline positions from recently launched blank checks to those approaching their outer windows. Biotech and pharma SPACs have consistently attracted sponsors with clinical and scientific backgrounds, making sponsor credentials a closely watched indicator for deal-watchers and investors. For comprehensive sponsor profiles, deal timelines, and real-time status updates on every active Biotech & Pharma SPAC, sign up for full data access at SpacDesk.
| SPAC | Sponsor | Trust | Status | IPO Date | Target | Deadline |
|---|---|---|---|---|---|---|
| DMII Drugs Made In America Acquisition II Corp. | Drugs Made In America Acquisition LLC | $575.0M | Searching | 2025-09-25 | — | 2027-09-25 |
| DMAA Drugs Made In America Acquisition Corp. | Drugs Made In America Acquisition LLC | $231.2M | Deal Announced | 2025-01-29 | Power Analytics Global Corp | 2026-04-29 |
| TDAC Translational Development Acquisition Corp. | Stone Capital Partners LLC | $174.2M | Deal Announced | 2024-12-23 | Prologium Holding Inc | 2026-06-23 |
| TKBD TechyBird Acquisition Corp. | TechyBird LLC | $60.3M | Searching | — | — | — |
| LPAA Launch One Acquisition Corp. | Launch One Sponsor LLC | — | Deal Announced | 2024-07-12 | Minovia Therapeutics Ltd | 2026-07-12 |
Active = status not liquidated/closed/withdrawn. Trust size reflects declared trust at IPO. Industry classification based on sponsor focus area and target company sector.